Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIN-101 phase 3 monotherapy study in adults with negative symptoms of schizophrenia
2017-003333-29Phase 3Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of roluperidone in schizophrenia, sponsored by Minerva Neurosciences, Inc.. Started Jan 2018; status: completed.
02
Drugs
roluperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2017-003333-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003333-29.